Product Introduction:
Herhope 2.5 mg Tablet contains Lapatinib, a tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. It works by blocking the HER2 receptor and other proteins that promote the growth of cancer cells. Herhope is typically used in combination with other cancer medications in patients who have progressed on other treatments. It is intended for use under strict medical supervision.
Uses:
-
HER2-positive metastatic breast cancer
-
Breast cancer in combination with Capecitabine or Letrozole
-
Cancer cases resistant to other HER2-targeted therapies
Benefits:
-
Inhibits growth of HER2-positive cancer cells
-
Slows progression of breast cancer
-
May be effective when other HER2 therapies have failed
-
Oral form allows outpatient management
Composition (per tablet):
-
Lapatinib 2.5 mg
Side Effects:
-
Diarrhea
-
Rash
-
Nausea and vomiting
-
Loss of appetite
-
Fatigue
-
Liver enzyme abnormalities
-
Heart-related issues (rare but serious)
Safety Advice:
-
Take exactly as prescribed by an oncologist
-
Swallow whole, on an empty stomach, at least 1 hour before or after meals
-
Liver function and cardiac monitoring required during treatment
-
Avoid during pregnancy and breastfeeding
-
Do not skip doses or stop treatment without medical advice
-
Store below 30°C, away from moisture and sunlight
